New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
Today's noteworthy upgrades include: Allergan (AGN) upgraded to Buy from Neutral at UBS... American Axle (AXL) upgraded to Neutral from Underweight at JPMorgan... Bank of Marin (BMRC) upgraded to Buy from Hold at Sandler O'Neill... CYS Investments (CYS) upgraded to Buy from Hold at Wunderlich... Diamondback Energy (FANG) upgraded to Buy from Neutral at Roth Capital... Digital Realty (DLR) upgraded to Buy from Hold at Deutsche Bank... Five Below (FIVE) upgraded to Outperform from Market Perform at Wells Fargo... Gas Natural (EGAS) upgraded to Buy from Hold at Wunderlich... Hasbro (HAS) upgraded to Overweight from Equal Weight at Barclays... Huntington Bancshares (HBAN) upgraded to Outperform at Keefe Bruyette... InnerWorkings (INWK) upgraded to Buy from Hold at Feltl... Realogy (RLGY) upgraded to Buy from Neutral at Citigroup... Sanmina (SANM) upgraded to Hold from Sell at Deutsche Bank... Trex Company (TREX) upgraded at Stifel... Ultra Clean (UCTT) upgraded to Buy from Neutral at Roth Capital... VCA Inc. (WOOF) upgraded at Stifel... Valspar (VAL) upgraded to Conviction Buy from Neutral at Goldman... Volvo (VOLVY) upgraded to Neutral from Sell at Goldman... Zions Bancorp (ZION) upgraded to Buy from Neutral at Compass Point.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
September 29, 2015
08:57 EDTAGNCowen lists Vertex, Biogen and Amgen as hypothetical Allergan targets
Cowen analyst Ken Cacciatore noted that the price agreed for Allergan's (AGN) generic divestiture to Teva (TEVA) is fixed and that the cash value from this deal has not depreciated in any way while the corresponding valuations of potential targets have corrected, increasing the potential value creation available for Allergan as it decides how to deploy its capital. To illustrate the value creation that Allergan's capital deployment could generate, Cacciatore estimates the type of accretion potential that might be seen if the company were to buy Vertex with an acquisition price of $36.5B, if it were to acquire Biogen (BIIB) at a price of $91B or if it were to purchase Amgen (AMGN) with an acquisition price of $140B. Although the market correction has lowered Allergan's stock, the decline could be viewed as a near-term positive, given that a key component of its strategy and business model is to seek to aggressively deploy its capital, Cacciatore argues in a note to investors. The analyst keeps an Outperform rating and $400 price target on Allergan shares.
08:18 EDTAGNAllergan initiated with a Buy at Nomura
Subscribe for More Information
08:03 EDTAGNAllergan price target lowered to $311 from $357 at Leerink
Subscribe for More Information
07:45 EDTDLRDigital Realty upgraded to Overweight from Sector Weight at KeyBanc
Subscribe for More Information
07:09 EDTAGNAllergan selloff brings 'compelling' buying opportunity, says JPMorgan
Subscribe for More Information
September 28, 2015
16:40 EDTAGNAllergan to begin reporting Global Generics business as discontinued ops in Q3
Allergan (AGN) intends to begin reporting its Global Generics business as discontinued operations with its third quarter 2015 results. The transaction with Teva (TEVA) is expected to close in the first quarter of 2016.
16:23 EDTAGNAllergan sees 10% branded revenue growth after divestiture of generics unit
Following the close of the divestiture of the Generics business to Teva (TEVA), New Allergan (AGN) expects to have a powerful financial profile to drive continued long-term growth: 10% branded revenue growth; Non-GAAP gross margins of 77% to 79% with additional long-term expansion anticipated; Non-GAAP SG&A as a percentage of revenue between 21-24%, declining within that range over time; Non-GAAP tax rate of ~15%; Interest expense for New Allergan will be largely dependent on capital deployment decisions following the close of the transaction; Commitment to investment grade ratings. "New Allergan will have strong double-digit revenue growth and will be a development powerhouse stacked with 70 mid-to-late stage R&D projects to address customer and patient needs," said Brent Saunders, CEO and President. "The New Allergan will be lean and nimble with an expanded margin profile driven by leading brands in seven therapeutic categories, a streamlined operating model with one of the most efficient SG&A as a percentage of sales in the industry, a non-GAAP tax rate of approximately 15 percent, and a simplified manufacturing network globally. The continued robust performance of our overall business and strong mid-to-late stage pipeline puts Allergan in a strong position to meet our growth targets for the remainder of the year and over the long-term."
16:21 EDTAGNAllergan sees 2H15 adjusted EPS $6.25-$6.65
Subscribe for More Information
07:52 EDTAGNIIR Holdings to hold a conference
Subscribe for More Information
06:57 EDTVOLVYNHTSA mulls Takata air bag recall expansion, Bloomberg reports
The National Highway Traffic Safety Administration, or NHTSA, is mulling an order that would expand that recalls of Takata (TKTDY) air bags and has contacted seven manufacturers who may be affected, including Volkswagen (VLKAY) and Tesla (TSLA), Bloomberg reports. Takata had identified seven companies that it has supplied with air bag inflators that use ammonium nitrate propellant, the report says, citing NHTSA letters dated September 22. The NHTSA also contacted Mercedes-Benz (DDAIF), Jaguar Land Rover (TTM), Suzuki (SZKMF), Volvo Trucks (VOLVY), and Spartan Motors (SPAR), the report says. Reference Link
September 25, 2015
12:39 EDTSANMElectronic contract manufacturers advance after Jabil reports earnings
Shares of contract electronic manufacturers Flextronics International (FLEX), Sanmina (SANM), and Celestica (CLS) are advancing after peer Jabil Circuit (JBL) posted quarterly earning last night that easily surpassed analysts' estimates. WHAT'S NEW: Jabil Circuit reported better-than-anticipated profit and revenue in the fourth quarter as revenue in its Diversified Manufacturing Services segment increased 47% on a year-over-year basis, and represented 41% of total company revenue. Jabil reported Q4 earnings per share of 53c on revenue of $4.68B against analysts' estimates of 45c and $4.55B. On the company's Q4 earnings conference call, Chief Executive Officer Mark Mondello said he anticipates continued growth across its DMS business, as the company "captures additional opportunities" in the markets that DMS serves. Mondello noted that those markets include audio, healthcare, consumer packaging, mobility, wearable technologies, and accessories. WHAT'S NOTABLE: Looking ahead, the company sees DMS in the first quarter up 33% year-over-year and guided to Q1 results that were far ahead of analysts' estimates. Jabil said it sees Q1 EPS of 72c-88c on revenue of $5.1B-$5.3B. Analysts were expecting EPS of 61c on revenue of $4.91B. Jabil also guided to fiscal year 2016 EPS of $2.60 ahead of expectations of $2.37. ANALYST TAKE: After Jabil reported higher than expected Q4 EPS, Stifel notes that the company's guidance for its November quarter was significantly above expectations. The firm thinks the company is benefiting from increased purchases of its diversified manufacturing products by Apple (AAPL). Stifel says that Apple is using Jabil's products for many of its products, not just iPhones, and it expects other customers to ramp up their purchases of the company's DMS products. Stifel kept a $25 price target and Buy rating on the shares. PRICE ACTION: Shares of Jabil Circuit are advancing almost 15% to $22.43 in midday trading. OTHERS TO WATCH: Shares of other contract manufacturers are also advancing, with Flextronics up 1.5%, Sanmina jumping 2.8%, and Celestica higher by 1.35%
08:00 EDTAGNAllergan launches generic version of INVEGA
Allergan announced that it has launched a generic version of Janssen's INVEGA in the U.S. Allergan is the first company to receive FDA approval for and launch a generic version of INVEGA, demonstrating the deep expertise of the Company's global generics R&D, regulatory and supply chain teams.
September 24, 2015
14:17 EDTAGNAppeals court affirms Shire Vyvanse patents valid until 2023
Subscribe for More Information
10:01 EDTTREXOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: 8point3 Energy (CAFD) upgraded to Market Perform from Underperform at Avondale... AEGON (AEG) upgraded to Buy from Neutral at Goldman... AMC Networks (AMCX) upgraded to Buy from Hold at Evercore ISI... Citi ups Ralph Lauren (RL) to Buy on valuation, cost savings... Kate Spade (KATE) upgraded to Overweight from Equal Weight at Stephens... L'Oreal (LRLCY) upgraded to Buy from Hold at Societe Generale... Marriott (MAR) upgraded on historical performance, growth outlook at SunTrust... Monster Beverage (MNST) upgraded to Buy from Neutral at Goldman... Nimble Storage (NMBL) upgraded to Buy from Neutral at Longbow... Qualys (QLYS) upgraded to Neutral from Underperform at Macquarie... Ralph Lauren (RL) upgraded to Buy from Neutral at Citi... Trex Company (TREX) upgraded to Outperform from Neutral at Wedbush... Valero Energy Partners (VLP) upgraded on better than expected transaction at SunTrust.
06:59 EDTTREXTrex Company upgraded to Outperform from Neutral at Wedbush
Subscribe for More Information
September 23, 2015
16:34 EDTHBANOn The Fly: Top stock stories for Wednesday
Stocks began the day in quiet fashion and remained that way during the first hour of trading. Following the release of the weekly energy inventory report, the averages moved lower and looked to be possibly setting up for another selloff. Positive comments on China's economy by its President, who is visiting the U.S., brought out buyers, who pared the market's losses. The averages finished slightly in the red in a day marked by low volume as a number of market participants may have been absent in observance of the Jewish holiday of Yom Kippur. ECONOMIC EVENTS: In the U.S., Markit's flash manufacturing purchasing manager's index was flat at 53.0 in September, which was slightly better than the expectation for it to dip to 52.8. EIA inventory data showed a 1.93M barrel fall in crude oil inventories, versus expectations for a weekly drawdown of 1.25M barrels. In China, Markit's flash manufacturing PMI fell to 47.0 in September from 47.3 last month. In Europe, Markit's composite PMI for the eurozone came in at 53.9 in the first look for September, down from 54.3 in August and below expectations for a reading of 54.1. COMPANY NEWS: Shares of Volkswagen (VLKAY) trading in New York rebounded 6.5% to $27.10 following the resignation of Chief Executive Officer Martin Winterkorn, with the company's supervisory board subsequently praising the decision and saying it will consider his replacement at a meeting Friday. Prior to the CEO change news, the stock was downgraded at research firms JPMorgan, Deutsche Bank and Natixis to hold or equivalent ratings this morning. Accounting for today's advance, U.S.-listed shares of Volkwagen are still down nearly 29% since last Friday, when the EPA publicly accused the automaker of equipping certain diesel cars sold in the U.S. with software that circumvented emissions standards... Against the backdrop of China's President Xi Jinping visiting the U.S., Boeing (BA) announced deals to sell 300 planes to three Chinese companies and set up an aircraft factory in China. The deals are possibly worth tens of billions of dollars in total and represent the largest total order the planemaker has received from Chinese companies, according to Reuters. The Wall Street Journal reported, citing people familiar with the matter, that Cisco (CSCO) plans to announce a partnership with Chinese server maker Inspur Group during President Xi Jinping's visit. MAJOR MOVERS: Among the notable gainers was First Niagara (FNFG), which advanced $1.30, or 14.5%, to $10.26 following a Bloomberg report that the company is exploring a sale. DealReporter noted that potential suitors include Toronto-Dominion Bank (TD), Huntington Bancshares (HBAN) and New York Community Bancorp (NYCB). BioMed Realty (BMR) gained $2.36, or 12.3%, to $21.54 after Bloomberg reported that the company is in talks to sell itself and has attracted attention from firms including Blackstone (BX). Heron Therapeutics (HRTX) rose $7.25, or 21.6%, to $40.81 after announcing that its Phase 2 study of HTX-011 for post-operative pain met its primary endpoint. Shares of a competitor Pacira (PCRX) declined 7.65% after the news, with several analysts remarking that Heron's data compares favorably versus Pacira's Exparel drug. Summit Midstream Partners (SMLP) declined $3.90, or 18.2%, to $17.52 following a Bloomberg report that Energy Capital Partners is seeking to sell its stake in the company. Synchronoss (SNCR) fell 10.75% to $33.37 after research firm Baird said it has become "increasingly concerned" that Verizon (VZ) is "no longer fully committed" to the white-label cloud product it offers in conjunction with the cloud services provider. INDEXES: The Dow fell 50.58, or 0.31%, to 16,279.89, the Nasdaq lost 3.98, or 0.08%, to 4,752.74, and the S&P 500 declined 3.98, or 0.2%, to 1,938.76.
14:52 EDTVOLVYNavistar slides after VW scandal makes potential takeover unlikely
Shares of truck maker Navistar (NAV) have been under pressure since the start of the Volkswagen (VLKAY) emissions probe. WHAT'S NOTABLE: Navistar, which is based in the U.S., has long been seen as a possible target of Volkswagen. Navistar would give Volkswagen a footing in the U.S commercial truck market and allow it to better compete with Daimler (DDAIF) and Volvo (VOLVY) in that sector. On March 5, shares of Navistar jumped after The Deal's senior transportation writer Lou Whiteman wrote that the company could become a target for Volkswagen, Daimler or PACCAR (PCAR). Earlier today, Dow Jones wrote that Volkswagen's growing scandal over diesel engine emissions will likely distract the German automaker's interest in Navistar. PRICE ACTION: Since September 18, when the EPA first announced it was issuing a notice of violation to Volkswagen, shares of Navistar are down approximately 19%. Navistar is at a 52-week low, down over 8% to $13.70 in afternoon trading.
09:05 EDTAGNAmgen and Allergan's lung cancer biosimilar candidate meets Phase 3 endpoints
Subscribe for More Information
05:56 EDTHBANFirst Niagara exploring possible sale, hires JPMorgan to advise, Bloomberg says
According to sources briefed on the situation, First Niagara (FNFG) is exploring a potential sale of the company as well as other opportunities, Bloomberg reports. The bank holding company has hired JPMorgan to advise on possible moves. A previous report from DealReporter said the bank had contacted potential suitors, including Toronto-Dominion Bank (TD), Huntington Bancshares (HBAN) and New York Community Bancorp (NYCB).
September 22, 2015
08:23 EDTAGNWith Pharma in 'hot seat,' Citi still likes Allergan, Teva
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use